These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 30554963)

  • 1. Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance.
    Gupta PB; Pastushenko I; Skibinski A; Blanpain C; Kuperwasser C
    Cell Stem Cell; 2019 Jan; 24(1):65-78. PubMed ID: 30554963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis.
    Lu W; Kang Y
    Dev Cell; 2019 May; 49(3):361-374. PubMed ID: 31063755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular Plasticity in Cancer.
    Yuan S; Norgard RJ; Stanger BZ
    Cancer Discov; 2019 Jul; 9(7):837-851. PubMed ID: 30992279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness.
    Liao TT; Yang MH
    Mol Oncol; 2017 Jul; 11(7):792-804. PubMed ID: 28649800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms.
    Nachiyappan A; Gupta N; Taneja R
    FEBS J; 2022 Mar; 289(5):1329-1351. PubMed ID: 34954891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics.
    BharathwajChetty B; Sajeev A; Vishwa R; Aswani BS; Alqahtani MS; Abbas M; Kunnumakkara AB
    Cancer Metastasis Rev; 2024 Mar; 43(1):321-362. PubMed ID: 38517618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression.
    Ye X; Weinberg RA
    Trends Cell Biol; 2015 Nov; 25(11):675-686. PubMed ID: 26437589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
    Navas T; Kinders RJ; Lawrence SM; Ferry-Galow KV; Borgel S; Hollingshead MG; Srivastava AK; Alcoser SY; Makhlouf HR; Chuaqui R; Wilsker DF; Konaté MM; Miller SB; Voth AR; Chen L; Vilimas T; Subramanian J; Rubinstein L; Kummar S; Chen AP; Bottaro DP; Doroshow JH; Parchment RE
    Cancer Res; 2020 Jan; 80(2):304-318. PubMed ID: 31732654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Epithelial-Mesenchymal Plasticity in Cancer Progression.
    Fontana R; Mestre-Farrera A; Yang J
    Annu Rev Pathol; 2024 Jan; 19():133-156. PubMed ID: 37758242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition.
    Chang JT; Mani SA
    Cancer Lett; 2013 Nov; 341(1):16-23. PubMed ID: 23499890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas.
    Jolly MK; Somarelli JA; Sheth M; Biddle A; Tripathi SC; Armstrong AJ; Hanash SM; Bapat SA; Rangarajan A; Levine H
    Pharmacol Ther; 2019 Feb; 194():161-184. PubMed ID: 30268772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMT Transition States during Tumor Progression and Metastasis.
    Pastushenko I; Blanpain C
    Trends Cell Biol; 2019 Mar; 29(3):212-226. PubMed ID: 30594349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Mechanisms by which EMT Programs Control Stemness.
    Wilson MM; Weinberg RA; Lees JA; Guen VJ
    Trends Cancer; 2020 Sep; 6(9):775-780. PubMed ID: 32312682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer.
    Zhou P; Li B; Liu F; Zhang M; Wang Q; Liu Y; Yao Y; Li D
    Mol Cancer; 2017 Feb; 16(1):52. PubMed ID: 28245823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies around epithelial-mesenchymal plasticity in cancer metastasis.
    Williams ED; Gao D; Redfern A; Thompson EW
    Nat Rev Cancer; 2019 Dec; 19(12):716-732. PubMed ID: 31666716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semaphorins as Regulators of Phenotypic Plasticity and Functional Reprogramming of Cancer Cells.
    Gurrapu S; Tamagnone L
    Trends Mol Med; 2019 Apr; 25(4):303-314. PubMed ID: 30824197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
    Mitra A; Mishra L; Li S
    Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem cell (CSC) resistance drivers.
    Najafi M; Mortezaee K; Majidpoor J
    Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance.
    Luo M; Brooks M; Wicha MS
    Curr Pharm Des; 2015; 21(10):1301-10. PubMed ID: 25506895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic Plasticity Determines Cancer Stem Cell Therapeutic Resistance in Oral Squamous Cell Carcinoma.
    Biddle A; Gammon L; Liang X; Costea DE; Mackenzie IC
    EBioMedicine; 2016 Feb; 4():138-45. PubMed ID: 26981578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.